Phone 204.453.1408 Fax 204.453.1546 info@miraculins.com



Miraculins Announces Closing of Private Placement Offering

WINNIPEG, Manitoba - July 14, 2015 - Miraculins Inc. (TSX-V:MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, has closed a private placement offering (the "Offering") with aggregate gross proceeds to the Company of \$350,000 from the sale of 4,375,000 units ("Units") at a price of \$0.08 per Unit. Each Unit is comprised of one common share of the Company (a "Share") and one Share purchase warrant (a "Warrant").

Each whole Warrant entitles the holder to purchase one Share at a price of \$0.10 per Share for a period of two years from the date the Warrant is issued. The Shares and Warrants will be restricted from transfer for a period of four months and a day from the date hereof in accordance with applicable securities laws. The net proceeds of the Offering shall be used for general corporate purposes.

A certain person assisted the Company by introducing potential subscribers for the Offering and was paid a finder's fee of 10% of the total subscription proceeds received from subscribers introduced to the Company by that person. Additionally, this person was issued compensation warrants ("Compensation Warrants") equal to 10% of the total number of Units subscribed for by subscribers introduced to the Company by this person. Each Compensation Warrant entitles the holder thereof to purchase one Share at a price of \$0.10 per Share for a period of one year from the date of issue. The Compensation Warrants will be restricted from transfer for a period of four months and a day from the date hereof in accordance with applicable securities laws.

The closing of the Offering is subject to the final approval of the TSX Venture Exchange.

For more information, please contact:

miraculins

Christopher J. Moreau President & CEO Miraculins Inc. Ph: 204-477-7599

Fax: 204-453-1596

info@miraculins.com www.miraculins.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.